Jelf
ADDInterims to March from corporate and financial consultant Jelf, which advises on insurance, healthcare and employee benefits, made pleasing reading for investors.
On turnover lifted 128% to £17.1m, the deal-hungry group, which also advises on commercial finance and wealth management, grew its EBITDA by 120% to £1.8m, driving adjusted pre-tax profits 80% higher to £1.3m. Though earnings growth was a modest 3% to 3.9p, this reflected a large increase in the average number of diluted shares in issue.
Jelf reported strong sales growth across all divisions, with the organic growth rate a respectable 24%. ‘We were particularly pleased with the organic growth in employee benefits and wealth management,’ remarked chief executive Alex Alway, whose strategy is to create shareholder value by acquiring well-run small brokerages at sensible prices. The group is then able to take advantage of economies of scale and cross-selling opportunities, while organic growth is captured through the ability to offer a wider range of services. Alway insists that recent acquisition SPS Wellbeing, a specialist healthcare and group risk intermediary bought for up to £10m, is performing ahead of expectations.
Investors should note Jelf’s results are significantly biased towards the second half, since April is a key month due to the start of the tax year and this year’s latter half will also reflect the benefits of recent acquisitions. For the year, Daniel Stewart’s Justin Bates expects Jelf to deliver adjusted profits of £6m and 16.2p of earnings, rising to £7.2m and 19.4p for 2008, placing the shares on forward ratings of 16.7 and 14. Undemanding for a company that is handsomely placed for growth as an independent and that could also prove attractive to a corporate predator over the longer term. Add.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £66.78m
PE Forecast: 16.7
Share price: 271.5p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
